Naxitamab
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers[1].
Product Specifications
CAS Number
[1879925-92-4]
Product Name Alternative
Naxitamab-gqgk; Humanized 3F8; Hu3F8
UNSPSC
12352203
Target
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/naxitamab.html
Purity
99.84
Solubility
10 mM in DMSO
Smiles
[Naxitamab]
Molecular Weight
(144.38 kDa)
References & Citations
[1]Cheung NK, et, al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012 Jul 1;1 (4) :477-486.|[2]Markham A. Naxitamab: First Approval. Drugs. 2021 Feb;81 (2) :291-296.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS2101731-02 5x 96 Tests + MBS2090685 (Ab Pairs Support Pack 1,5x 96 Tests)
Human Grancalcin (GCA) Antibody Pair Kit (with Standard)
Ask
View Details MBS2101731-03 10x 96 Tests
Human Grancalcin (GCA) Antibody Pair Kit (with Standard)
Ask
View Details MBS2101731-04 10x 96 Tests + MBS2090685 (Ab Pairs Support Pack 1, 10x 96 Tests)
Human Grancalcin (GCA) Antibody Pair Kit (with Standard)
Ask
View Details 